The intended target audience for this program is US dermatologists and NP/PAs who treat patients with AA.
The goal of this program is for learners to demonstrate and improve their application of knowledge, clinical performance, and confidence in making treatment decisions to optimize the treatment of patients with AA.
Upon completion of this activity, participants should be able to:
Formulate an accurate diagnosis and classification of AA based on multiple disease and patient factors
Detail factors that may predict a patient’s positive or negative response to JAK inhibitor therapy for AA
Evaluate patients with AA for treatment candidacy with JAK inhibitor therapy
Brittany Craiglow, MD
Associate Adjunct Professor
Department of Dermatology
Yale School of Medicine
New Haven, Connecticut
Brittany Craiglow, MD: consultant/advisor/speaker: AbbVie, Concert Pharmaceuticals, Incyte, Lilly, Pfizer, Regeneron, Sanofi-Genzyme.
Maryanne Makredes Senna, MD, FAAD
Assistant Professor of Dermatology
Harvard Medical School
Director, Lahey Hair Loss Center of Excellence
Lahey Hospital and Medical Center
Maryanne Makredes Senna, MD, FAAD: consultant/advisor/speaker: AbbVie, Kintor, L’Oréal, Lilly, Pfizer, Inmagene.